Segment, Geographic and Other Revenue Information

6 Months Ended

Jun. 29, 2025

Segment Reporting [Abstract]

Segment, Geographic and Other Revenue Information

Segment, Geographic and Other Revenue Information

A. Segment Information

We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Pfizer Ignite is an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with Pfizer’s R&D focus areas. Biopharma is the only reportable segment. We regularly review our operating segments and the approach used by management to evaluate performance and allocate resources.

Our commercial divisions market, sell and distribute our products, and global operating functions are responsible for the research, development, manufacturing and supply of our products. Each operating segment is supported by our global corporate enabling functions. At the beginning of 2025, we made the following changes within our Biopharma reportable segment that went into effect on January 1, 2025 to support our continued focus on commercial execution and to further strengthen Pfizer’s capabilities and leadership in discovering and developing breakthrough medicines and vaccines:

•transitioned all activities within the former Pfizer Oncology Division to other parts of Biopharma. Specifically, within our Biopharma reportable segment the U.S. Oncology commercial organization and the global Oncology marketing organization, which were part of the former Pfizer Oncology Division, are now part of the Pfizer U.S. Commercial Division. As of January 1, 2025, the commercial structure within our Biopharma reportable segment is now comprised of the Pfizer U.S. Commercial Division, which now focuses on the commercialization of Pfizer’s entire product portfolio in the U.S. and is led by the Chief U.S. Commercial Officer, Executive Vice President, and the Pfizer International Commercial Division, which focuses on the commercialization of Pfizer’s entire product portfolio in all international markets and is led by the Chief International Commercial Officer, Executive Vice President.

•strategically combined our former global Oncology Research and Development (ORD) and Pfizer Research and Development (PRD) divisions to form a single Pfizer R&D organization led by the Chief Scientific Officer and President, Research and Development. This organization is responsible for overseeing all R&D activities with end-to-end responsibilities that span from discovery to late-phase clinical development, including facilitating regulatory submissions, engaging with health authorities and global medical strategies. The R&D organization also includes science-based disciplines, providing comprehensive technical expertise for the development of Pfizer's medicines and vaccines. A newly formed Chief Medical Office is part of this structure, advancing medical and scientific knowledge by generating evidence-based insights to drive informed regulatory and healthcare decisions. It ensures all stakeholders – including patients, healthcare providers, pharmacists, payors, and health authorities – have complete and up-to-date information on the benefits and risks associated with our products. R&D spending may encompass upfront and pre-approval milestone payments for intellectual property rights related to its programs which would be recorded as Acquired in-process research and development expenses.

Other Business Activities and Reconciling Items––Other business activities include the operating results of PC1 and Pfizer Ignite as well as certain pre-tax costs not allocated to our operating segment results, such as costs associated with corporate enabling functions and other corporate costs, as well as for the three and six months ended June 30, 2024, our share of earnings from Haleon. In 2025, Pfizer made the decision to discontinue Pfizer Ignite and has begun winding down this business while collaborating closely with our Ignite partners to ensure continuity and the successful transition of work. Reconciling items include the following items, transactions and events that are not allocated to our operating segments: (i) all amortization of intangible assets; (ii) acquisition-related items; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

Segment Assets––We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $206 billion as of June 29, 2025 and $213 billion as of December 31, 2024.

Selected Statement of Operations Information

The following provides selected information by reportable segment:
	Three Months Ended
	Total Revenues				Earnings(a)				Depreciation and Amortization(b)
(MILLIONS)	June 29, 2025		June 30, 2024		June 29, 2025		June 30, 2024		June 29, 2025		June 30, 2024
Reportable Segment:
Biopharma(c)	$	14,305	$	12,991	$	6,929	$	5,897	$	339	$	330
Other business activities(d)	348		292		(1,799)		(1,985)		73		91
Reconciling Items:
Amortization of intangible assets					(1,211)		(1,307)		1,211		1,307
Acquisition-related items					(338)		(617)		(2)		1
Certain significant items(e)					(537)		(2,091)		3		1
	$	14,653	$	13,283	$	3,044	$	(103)	$	1,625	$	1,730

	Six Months Ended
	Total Revenues				Earnings(a)				Depreciation and Amortization(b)
(MILLIONS)	June 29, 2025		June 30, 2024		June 29, 2025		June 30, 2024		June 29, 2025		June 30, 2024
Reportable Segment:
Biopharma(c)	$	27,746	$	27,595	$	14,033	$	13,519	$	671	$	667
Other business activities(d)	622		567		(3,220)		(3,992)		147		177
Reconciling Items:
Amortization of intangible assets					(2,421)		(2,615)		2,421		2,615
Acquisition-related items					(620)		(1,125)		(3)		2
Certain significant items(e)					(1,944)		(2,469)		7		5
	$	28,367	$	28,162	$	5,828	$	3,318	$	3,243	$	3,467

(a)Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss).

(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.

(c)Biopharma’s earnings in the first six months of 2025 reflect a credit to Cost of sales representing a favorable revision of our estimate of accrued royalties. Biopharma’s revenues and earnings in the first six months of 2024 reflected a non-cash favorable product return adjustment of $771 million (see Note 13C). Biopharma’s earnings also include dividend income from our investment in ViiV of $73 million in the second quarter of 2025 and $74 million in the second quarter of 2024, and $111 million in the first six months of 2025 and $135 million in the first six months of 2024 recorded in Other (income)/deductions––net.

(d)Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.

(e)Earnings in the first six months of 2025 include, among other items, restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $670 million (primarily recorded in Restructuring charges and certain acquisition-related costs) and charges for certain legal matters of $564 million recorded in Other (income)/deductions––net. Earnings in the second quarter and the first six months of 2024 included, among other items, restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs). See Notes 3 and 4.

The following provides Biopharma reportable segment information regularly provided to the CODM:
	Three Months Ended				Six Months Ended
(MILLIONS)	June 29, 2025		June 30, 2024		June 29, 2025		June 30, 2024
Biopharma reportable segment:
Biopharma total revenues	$	14,305	$	12,991	$	27,746	$	27,595
Less:
Cost of sales	3,075		2,411		5,389		5,054
Selling, informational and administrative expenses	2,305		2,473		4,455		4,808
Research and development expenses	2,109		2,293		4,050		4,445
Acquired in-process research and development expenses	2		7		11		7
Other (income)/deductions––net	(115)		(90)		(193)		(237)
Biopharma earnings	$	6,929	$	5,897	$	14,033	$	13,519

B. Geographic Information

The following summarizes revenues by geographic area:
	Three Months Ended				Six Months Ended
(MILLIONS)	June 29, 2025		June 30, 2024		June 29, 2025		June 30, 2024
United States	$	8,894	$	7,892	$	17,268	$	17,406
International:
Developed Markets	3,393		3,164		6,571		6,362
Emerging Markets	2,366		2,227		4,529		4,394
Total revenues	$	14,653	$	13,283	$	28,367	$	28,162

C. Other Revenue Information

Significant Revenues by Product

The following provides detailed revenue information for several of our major products:

(MILLIONS)		Three Months Ended				Six Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	June 29, 2025		June 30, 2024		June 29, 2025		June 30, 2024
TOTAL REVENUES		$	14,653	$	13,283	$	28,367	$	28,162
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)		$	14,305	$	12,991	$	27,746	$	27,595
Primary Care		$	5,540	$	4,952	$	11,236	$	12,163
Eliquis(a)	Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism	2,003		1,877		3,926		3,917
Prevnar family	Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae	1,383		1,359		3,043		3,050
Comirnaty	Active immunization to prevent COVID-19	381		195		945		548
Paxlovid(b)	COVID-19 in certain high-risk patients	427		251		918		2,286
Nurtec ODT/Vydura	Acute treatment of migraine and prevention of episodic migraine	359		356		607		533
Abrysvo	Active immunization to prevent RSV infection	143		56		274		201
FSME-IMMUN/TicoVac	Active immunization to prevent tick-borne encephalitis disease	109		100		172		165
All other Primary Care	Various	736		759		1,350		1,463
Specialty Care		$	4,378	$	4,083	$	8,364	$	7,926
Vyndaqel family	ATTR-CM and polyneuropathy	1,615		1,323		3,101		2,460
Xeljanz	RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis	322		303		450		497
Sulperazon (Outside the U.S. and Canada)	Bacterial infections	166		144		330		311
Zavicefta (Outside the U.S. and Canada)	Bacterial infections	163		150		299		275
Enbrel (Outside the U.S. and Canada)	RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis	154		179		294		338
Inflectra	Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis	139		97		291		255
Zithromax	Bacterial infections	56		74		213		274
Genotropin	Replacement of human growth hormone	106		119		201		239
Cresemba	Invasive aspergillosis and mucormycosis	111		71		184		146
Cibinqo	Atopic dermatitis	69		47		127		89
All other Hospital	Various	1,087		1,146		2,170		2,221
All other Specialty Care	Various	390		429		705		821
Oncology		$	4,387	$	3,956	$	8,145	$	7,505
Ibrance	HR-positive/HER2-negative metastatic breast cancer	1,049		1,130		2,026		2,184
Xtandi(c)	mCRPC, nmCRPC, mCSPC, nmCSPC	566		495		1,023		913
Padcev	Locally advanced or metastatic urothelial cancer	542		394		967		735
Oncology biosimilars(d)	Various	353		279		617		543
Lorbrena	ALK-positive metastatic NSCLC	251		169		473		332
Adcetris(e)	Certain lymphomas including classical hodgkin lymphoma, T-cell lymphoma and relapsed/refractory diffuse large B-cell lymphoma	255		279		472		536
Inlyta	Advanced renal cell carcinoma	243		252		462		489
Braftovi/Mektovi	Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux® (cetuximab)(f) (after prior therapy) or cetuximab and mFOLFOX6	182		148		317		264

(MILLIONS)		Three Months Ended				Six Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	June 29, 2025		June 30, 2024		June 29, 2025		June 30, 2024
Bosulif	Philadelphia chromosome–positive chronic myelogenous leukemia	149		167		300		313
Tukysa	Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer	132		121		234		227
Aromasin	Post-menopausal early and advanced breast cancer	111		87		219		170
Elrexfio	Relapsed or refractory multiple myeloma	85		22		145		35
Talzenna	Treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer; and, in combination with Xtandi (enzalutamide), of adult patients with HRR gene-mutated mCRPC	46		32		86		55
Tivdak	Recurrent or mCC	46		33		79		60
All other Oncology	Various	380		347		725		648
PFIZER CENTREONE(g)		$	328	$	278	$	585	$	535
PFIZER IGNITE		$	20	$	15	$	37	$	32
BIOPHARMA		$	14,305	$	12,991	$	27,746	$	27,595
PFIZER U.S. COMMERCIAL DIVISION(h)		8,793		7,828		17,078		17,254
PFIZER INTERNATIONAL COMMERCIAL DIVISION		5,512		5,163		10,668		10,341
Total Alliance revenues included above		$	2,273	$	2,067	$	4,386	$	4,240
Total Royalty revenues included above		$	426	$	345	$	734	$	608

(a)Reflects alliance revenues and product revenues.

(b)The amount for the first six months of 2024 included a $771 million favorable final adjustment to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.

(c)Primarily reflects alliance revenues and royalty revenues.

(d)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Retacrit, Zirabev, Trazimera and Nivestym.

(e)Reflects product revenues and royalty revenues.

(f)Erbitux® is a registered trademark of ImClone LLC.

(g)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.

(h)Refer to Note 13A above.

Remaining Performance Obligations––Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty and Paxlovid to our customers totaled approximately $4 billion and $1 billion, respectively, as of June 29, 2025, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of these amounts, current contract terms provide for expected delivery of product with contracted revenue from 2025 through 2031, the timing of which may be renegotiated. Remaining performance obligations are based on foreign exchange rates as of the end of our fiscal second quarter of 2025 and exclude arrangements with an original expected contract duration of less than one year. Remaining performance obligations associated with contracts for other products and services were not significant as of June 29, 2025 or December 31, 2024.

Deferred Revenues––Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers for supply of Paxlovid and Comirnaty. The deferred revenues related to Paxlovid and Comirnaty totaled $1.9 billion as of June 29, 2025, with $1.0 billion and $906 million recorded in current liabilities and noncurrent liabilities, respectively. The deferred revenues related to Paxlovid and Comirnaty totaled $2.2 billion as of December 31, 2024, with $1.4 billion and $785 million recorded in current liabilities and noncurrent liabilities, respectively. The decrease in Paxlovid and Comirnaty deferred revenues during the first six months of 2025 was primarily driven by amounts recognized in Product revenues as we delivered the products to our customers. During the second quarter and the first six months of 2025, we recognized revenue of approximately $45 million and $380 million, respectively, that was included in the balance of Paxlovid and Comirnaty deferred revenues as of December 31, 2024. The Paxlovid and Comirnaty deferred revenues as of June 29, 2025 will be recognized in Product revenues proportionately as we transfer control of the products to our customers and satisfy our performance obligations under the contracts, with the amounts included in current liabilities expected to be recognized in Product revenues within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in Product revenues from 2026 through 2028. Deferred revenues associated with contracts for other products were not significant as of June 29, 2025 or December 31, 2024.